Allogene Therapeutics (ALLO) stock price, revenue, and financials

Allogene Therapeutics market cap is $3.5 b.

$3.5 B

ALLO Mkt cap, 18-Jun-2021

Allogene Therapeutics Revenue Q1, 2021

Allogene Therapeutics Net income (Q1, 2021)-33 M

Allogene Therapeutics EBIT (Q1, 2021)-33.2 M

Allogene Therapeutics Cash, 31-Mar-2021236.9 M

Allogene Therapeutics EV3.3 B

USD	FY, 2017	FY, 2018	FY, 2019	FY, 2020
R&D expense		151.9m	144.5m	193.0m
General and administrative expense	2.0k	41.0m	57.5m	65.3m
Operating expense total	2.0k	192.8m	202.0m	258.2m
EBIT	(2.0k)	(192.8m)	(202.0m)	(258.2m)
Interest expense		3.4m
Pre tax profit	(2.0k)	(211.6m)	(184.9m)	(250.2m)
Income tax expense		(117.0k)	(331.0k)
Net Income	(2.0k)	(211.5m)	(183.8m)	(250.2m)
EPS		(7.3)	(1.8)

USD	Q1, 2018	Q2, 2018	Q3, 2018	Q1, 2019	Q2, 2019	Q3, 2019	Q1, 2020	Q2, 2020	Q3, 2020	Q1, 2021
Revenue										38.3m
R&D expense		122.5m	10.9m	23.4m	31.8m	40.0m	42.0m	47.3m	51.4m	55.2m
General and administrative expense	2.6m	12.5m	11.3m	13.1m	14.2m	15.0m	15.6m	15.9m	16.6m	16.4m
Operating expense total	2.6m	135.0m	22.2m	36.5m	46.0m	55.0m	57.7m	63.2m	68.0m	71.5m
EBIT	(2.6m)	(135.0m)	(22.2m)	(36.5m)	(46.0m)	(55.0m)	(57.7m)	(63.2m)	(68.0m)	(33.2m)
EBIT margin, %										(87%)
Interest expense			3.4m
Pre tax profit	(2.6m)	(134.9k)	(43.5m)	(31.6m)	(41.4m)	(50.7m)	(54.5m)	(61.0m)	(66.2m)
Income tax expense				(50.0k)	(159.0k)	33.0k
Net Income	(2.6m)	(134.9k)	(43.5m)	(30.5m)	(40.5m)	(51.0m)	(54.5m)	(61.0m)	(66.2m)	(33.0m)

USD	FY, 2017	FY, 2018	FY, 2019	FY, 2020
Cash		92.4m	175.1m	183.4m
Prepaid Expenses				17.2m
Current Assets		468.0m	544.6m	845.1m
PP&E		8.6m	56.4m	118.8m
Total Assets		773.9m	717.8m	1.2b
Accounts Payable		12.3m	9.3m	10.4m
Current Liabilities	2.0k	29.5m	33.1m	94.3m
Long-term debt		34.5m	51.3m	50.8m
Total Debt		34.5m	51.3m	50.8m
Total Liabilities	2.0k	70.7m	88.8m	148.2m
Common Stock	5.0k	121.0k	124.0k	140.0k
Preferred Stock
Additional Paid-in Capital		914.3m	1.0b	1.7b
Retained Earnings	(2.0k)	(211.5m)	(396.1m)	(646.3m)
Total Equity	(2.0k)	703.2m	629.0m	1.1b
Debt to Equity Ratio		0 x	0.1 x
Debt to Assets Ratio		0 x	0.1 x
Financial Leverage		1.1 x	1.1 x	1.1 x

USD	Q2, 2018	Q3, 2018	Q1, 2019	Q2, 2019	Q3, 2019	Q1, 2020	Q2, 2020	Q3, 2020	Q1, 2021
Cash	143.9m	83.1m	92.7m	112.6m	161.0m	135.9m	280.4m	158.1m	236.9m
Prepaid Expenses						11.5m	9.9m	13.0m	16.5m
Current Assets	144.3m	247.4m	476.6m	511.5m	509.8m	504.4m	909.6m	854.1m	716.1m
PP&E	3.5m	4.7m	20.4m	35.8m	45.9m	66.3m	84.6m	102.7m	123.1m
Total Assets	148.8m	435.2m	749.4m	734.0m	695.5m	688.5m	1.3b	1.2b	1.2b
Accounts Payable	1.3m	3.1m	13.0m	23.5m	8.0m	7.2m	9.1m	10.2m	14.9m
Short-term debt		139.6m				1.8m
Current Liabilities	14.7m	159.5m	27.3m	38.0m	33.4m	26.8m	40.9m	50.1m	54.8m
Long-term debt		25.7m	34.8m	34.9m	37.7m	51.5m	51.1m	50.8m	51.6m
Total Debt		165.3m	34.8m	34.9m	37.7m	53.3m	51.1m	50.8m	51.6m
Total Liabilities	17.2m	192.6m	68.1m	78.4m	75.8m	82.0m	95.1m	103.8m	109.3m
Common Stock	5.0k	31.0k	121.0k	122.0k	122.0k	125.0k	139.0k	140.0k	141.0k
Preferred Stock	411.1m	411.1m
Additional Paid-in Capital	8.1m	12.7m	922.8m	937.7m	952.8m	1.1b	1.7b	1.7b	1.7b
Retained Earnings	(137.5m)	(181.0m)	(243.1m)	(284.4m)	(335.1m)	(450.6m)	(511.6m)	(577.8m)	(679.4m)
Total Equity	(129.4m)	(168.4m)	681.2m	655.6m	619.7m	606.5m	1.2b	1.1b	1.1b
Debt to Equity Ratio		-1 x	0.1 x	0.1 x	0.1 x
Debt to Assets Ratio		0.4 x	0 x	0 x	0.1 x
Financial Leverage	-1.1 x	-2.6 x	1.1 x	1.1 x	1.1 x	1.1 x	1.1 x	1.1 x	1.1 x

USD	FY, 2017	FY, 2018	FY, 2019	FY, 2020
Net Income	(2.0k)	(211.5m)	(184.6m)	(250.2m)
Depreciation and Amortization		1.5m	5.0m	7.6m
Accounts Payable		8.8m	(985.0k)	615.0k
Cash From Operating Activities		(44.7m)	(137.3m)	(115.1m)
Purchases of PP&E		(3.2m)	(50.8m)	(66.0m)
Cash From Investing Activities		(632.8m)	164.1m	(505.1m)
Cash From Financing Activities		771.2m	59.0m	633.6m
Net Change in Cash		93.7m	85.7m	13.4m
Income Taxes Paid		(117.0k)	(331.0k)

USD	Q1, 2018	Q2, 2018	Q3, 2018	Q1, 2019	Q2, 2019	Q3, 2019	Q1, 2020	Q2, 2020	Q3, 2020	Q1, 2021
Net Income	(2.6m)	(137.5m)	(181.0m)	(31.6m)	(72.8m)	(123.6m)	(54.5m)	(115.5m)	(181.7m)	(33.0m)
Depreciation and Amortization		450.0k	953.0k	695.0k	1.8m	3.2m	2.0m	3.9m	5.7m	1.9m
Accounts Payable		1.3m	3.1m	(348.0k)	1.3m	(3.1m)	(1.0m)	(503.0k)	1.7m	4.2m
Cash From Operating Activities	5.0k	(6.0m)	(23.2m)	(30.3m)	(55.1m)	(87.1m)	(40.8m)	(67.5m)	(105.1m)	(49.3m)
Purchases of PP&E		(536.0k)	(1.9m)	(10.4m)	(18.3m)	(36.7m)	(12.3m)	(28.3m)	(48.6m)	(6.5m)
Cash From Investing Activities		(2.6m)	(319.4m)	32.9m	77.4m	156.2m	(15.0m)	(444.0m)	(527.3m)	96.8m
Cash From Financing Activities		152.6m	426.7m	684.0k	920.0k	2.5m	16.6m	616.8m	620.6m	6.0m
Net Change in Cash	5.0k	143.9m	84.1m	3.3m	23.2m	71.6m	(39.2m)	105.3m	(11.8m)	53.5m

	Sep, 2018	FY, 2018	FY, 2019
Patients Included in Clinical Trials	18	21	21
Pre-Clinical Phase Products	7	7	8
Phase I Trials Products	1	1	4
Office and Laboratory Space, square feet	89.54 k	222.49 k	200.94 k